The analysis of all batches of anti-leukemia CTLs produced so far documented that the majority of effector cells were CD3+/CD8+ cells, with a memory/terminal activated phenotype displaying efficient capacity to lyse patients’ LB and to secrete IFNγ and TNFα in response to leukemia cells. The gene discussed is TNF; the disease is leukemia.